Anders Fink Vadsholt
Corporate Officer/Principal chez Alpha Healthcare Investments ApS
Profil
Anders Fink Vadsholt is the founder of 7TM A, which was founded in 2000.
He is currently the owner of Alpha Healthcare Investments ApS and a partner at Obton Solenergi Sinope Komplementaranpartsselskab.
In the past, he served as the Chief Executive Officer of LEO Pharma A, Director of Zealand Pharma A, Director of OxThera AB, Chief Financial Officer & EVP-Corporate Affairs of Topotarget A, Chief Executive & Financial Officer of Orphazyme A, Partner of Bankinvest Biomedical Venture, Owner of Lakeside Invest ApS, and Member-Management Board of Copenhagen Innovation Capital Management ApS.
He holds an MBA degree from the University of Melbourne and a graduate degree from Copenhagen Business School.
Postes actifs de Anders Fink Vadsholt
| Sociétés | Poste | Début |
|---|---|---|
Alpha Healthcare Investments ApS
 Alpha Healthcare Investments ApS Miscellaneous Commercial ServicesCommercial Services Alpha Healthcare Investments ApS provides business and management consulting services. The private company is based in Virum, Denmark. | Corporate Officer/Principal | 01/01/2015 |
| Obton Solenergi Sinope Komplementaranpartsselskab | Corporate Officer/Principal | 01/01/2015 |
Anciens postes connus de Anders Fink Vadsholt
| Sociétés | Poste | Fin |
|---|---|---|
| ORPHAZYME A/S | Chief Executive Officer | 01/10/2023 |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Chief Executive Officer | 01/01/2022 |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Director/Board Member | 01/01/2021 |
Lakeside Invest ApS
 Lakeside Invest ApS Financial ConglomeratesFinance Lakeside Invest ApS provides financial services. | Corporate Officer/Principal | 01/01/2018 |
| Copenhagen Innovation Capital Management ApS | Corporate Officer/Principal | 01/01/2018 |
Formation de Anders Fink Vadsholt
| University of Melbourne | Masters Business Admin |
| Copenhagen Business School | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ZEALAND PHARMA A/S | Health Technology |
| ORPHAZYME A/S | Health Technology |
| Entreprise privées | 9 |
|---|---|
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
7TM A/S
 7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Health Technology |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
Bankinvest Biomedical Venture
 Bankinvest Biomedical Venture Investment ManagersFinance Bankinvest Biomedical Venture provides investment services. The company was founded in 1998 and is headquartered in Copenhagen, Denmark. | Finance |
Alpha Healthcare Investments ApS
Alpha Healthcare Investments ApS Miscellaneous Commercial ServicesCommercial Services Alpha Healthcare Investments ApS provides business and management consulting services. The private company is based in Virum, Denmark. | Commercial Services |
Lakeside Invest ApS
Lakeside Invest ApS Financial ConglomeratesFinance Lakeside Invest ApS provides financial services. | Finance |
| Obton Solenergi Sinope Komplementaranpartsselskab | |
| Copenhagen Innovation Capital Management ApS |
